Department of Microbiology, Pushpagiri Institute of Medical Sciences and Research Centre, Thiruvalla, Kerala, India.
Pushpagiri Centre for Evidence-based Practice (PCEBP): A JBI Centre of Excellence, Pushpagiri Institute of Medical Sciences and Research Centre, Thiruvalla, Kerala, India.
JBI Evid Synth. 2022 Nov 1;20(11):2721-2726. doi: 10.11124/JBIES-22-00018.
The objective of this review is to determine the incidence and prevalence, clinical features, and outcomes of COVID-19 in persons with cystic fibrosis.
Cystic fibrosis, predominantly a chronic respiratory illness, has long been known to be fatal with concomitant bacterial or viral infections. Consequently, the effects of COVID-19 on this protracted disease need to be understood, especially since the major manifestations affect the respiratory system. Hence, this review aims to examine the burden, clinical features, and outcomes of COVID-19 on individuals with cystic fibrosis.
This review will consider studies of persons in all age groups with preexisting cystic fibrosis who are diagnosed with COVID-19 using either a polymerase chain reaction, serology, or point-of-care test for SARS-CoV-2. Eligible studies will report the incidence, prevalence, clinical features, or outcomes of COVID-19 in individuals with cystic fibrosis. Studies in community or health care settings from any geographic location will be considered.
The JBI methodology for systematic reviews of prevalence and incidence will be used for this review. A methodical search for eligible studies in English (as well as available translations) in MEDLINE, Embase, Scopus, and CINAHL, and unpublished literature in Google Scholar, Dissertation Abstracts International, ProQuest Dissertations and Theses, and MedNar will be conducted from the year 2020 onwards. Studies meeting the inclusion criteria will be selected for appraisal and their methodological quality will be assessed by two independent reviewers based on study titles and abstracts, followed by full-text review focusing on sampling and statistical analysis. Data extraction will be accomplished using a standardized tool. If adequate synthesized data are obtained, a meta-analysis will be conducted; otherwise, the findings will be presented in narrative format, including tables and figures to aid in data presentation.
PROSPERO CRD42021237792.
本综述旨在确定 COVID-19 在囊性纤维化患者中的发病率和患病率、临床特征和结局。
囊性纤维化主要是一种慢性呼吸系统疾病，长期以来，伴有细菌或病毒感染时，囊性纤维化是致命的。因此，需要了解 COVID-19 对这种慢性疾病的影响，特别是因为主要表现影响呼吸系统。因此，本综述旨在检查 COVID-19 对囊性纤维化患者的负担、临床特征和结局。
本综述将考虑所有年龄段患有预先存在的囊性纤维化的患者的研究，这些患者使用聚合酶链反应、血清学或即时 SARS-CoV-2 检测诊断为 COVID-19。符合条件的研究将报告囊性纤维化患者 COVID-19 的发病率、患病率、临床特征或结局。将考虑来自任何地理位置的社区或医疗保健环境中的研究。
本综述将使用 JBI 系统评价发病率和患病率的方法进行。将对 2020 年以来在 MEDLINE、Embase、Scopus 和 CINAHL 中的英文（以及可用翻译）以及 Google Scholar、Dissertation Abstracts International、ProQuest Dissertations 和 Theses 以及 MedNar 中的未发表文献进行系统搜索，以寻找符合纳入标准的研究。将由两名独立评审员根据研究标题和摘要选择符合纳入标准的研究进行评估，并评估其方法学质量，然后进行全文审查，重点关注抽样和统计分析。使用标准化工具进行数据提取。如果获得足够的综合数据，将进行荟萃分析；否则，将以叙述形式呈现研究结果，包括表格和图形以帮助呈现数据。
PROSPERO CRD42021237792。
